Dimethyl Fumarate Capsule, Delayed Release
Product Images NDC 82249-745

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Dimethyl Fumarate (NDC 82249-745). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Civicascript Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Dmf-120mg-14cap (Dmf 120mg 14cap)

Dmf-120mg-14cap (Dmf 120mg 14cap)
Label for Dimethyl Fumarate delayed-release capsules, 120 mg strength, supplied as a 14-capsule bottle. The label includes dosage instructions, storage conditions, and manufacturer information (Alkem Laboratories Ltd., India). Distributed by CivicaScript LLC. It features a QR code linking to product information and displays the National Drug Code (NDC 82249-745-14).*
FDA Label Image

Dmf-240mg-60cap (Dmf 240mg 60cap)

Dmf-240mg-60cap (Dmf 240mg 60cap)
Label for Dimethyl Fumarate 240 mg delayed-release capsules by CivicaScript LLC. The label includes dosage instructions, storage conditions, distributor and manufacturer information, a barcode, and a QR code for additional information. The package contains 60 capsules intended for oral use.*
FDA Label Image

Dmf-f1 (Dmf F1)

Dmf-f1 (Dmf F1)
Chemical structure of Dimethyl fumarate, showing its molecular composition and arrangement of atoms, corresponding to the active ingredient in the drug capsules labeled under the same name.*
FDA Label Image

Dmf-f2 (Dmf F2)

Dmf-f2 (Dmf F2)
A line graph showing the percentage of subjects with confirmed progression of disability over time in weeks (up to 96) during a study. Two groups are compared: placebo (n=408) and Dimethyl fumarate delayed release capsules 240 mg BID (n=409). The percentage of subjects with disability progression reaches 27.1% for placebo and 16.4% for the Dimethyl fumarate group by week 96.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.